Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0000516

Glimepiride for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Glimepiride

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C24H34N4O5S
Número de CAS:
93479-97-1
Peso molecular:
490.62
Número MDL:
MFCD00878417
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329830997
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

glimepiride

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

Clave InChI

WIGIZIANZCJQQY-RUCARUNLSA-N

Información sobre el gen

human ... ABCC8(6833) , KCNJ11(3767)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Glimepiride is currently used to treat type 2 diabetes.

Acciones bioquímicas o fisiológicas

Glimepiride is a potent blocker of cardiac KATP channels activated by pinacidil with an IC50 of 6.8 nM.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

1292303

Glimepiride, United States Pharmacopeia (USP) Reference Standard

1292325

Glimepiride Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0000515

Glimepiride, European Pharmacopoeia (EP) Reference Standard

1292314

Glimepiride Related Compound A, United States Pharmacopeia (USP) Reference Standard

1292336

Glimepiride Related Compound C, United States Pharmacopeia (USP) Reference Standard

1292347

Glimepiride Related Compound D, United States Pharmacopeia (USP) Reference Standard

Y0001742

Glimepiride for impurity A identification, European Pharmacopoeia (EP) Reference Standard

PHR1617

Glimepiride, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1727

Glimepiride Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1725

Glimepiride cis-Isomer (Glimepiride Related Compound A), Pharmaceutical Secondary Standard; Certified Reference Material

BP1144

Glimepiride, British Pharmacopoeia (BP) Reference Standard

PHR1726

Glimepiride Sulfonamide, pharmaceutical secondary standard, certified reference material

Pictogramas

Health hazard
GHS08

Palabra de señalización

Warning

Frases de peligro

H361

Clasificaciones de peligro

Repr. 2

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

W Rathmann et al.
Diabetes, obesity & metabolism, 15(1), 55-61 (2012-08-07)
To investigate therapy persistence, frequency of hypoglycaemia and macrovascular outcomes among type 2 diabetes patients with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4) and sulphonylureas (SU). Data from 19,184 DPP-4 (mean age: 64 years; 56% males) and 31,110 SU users (69 years;
J Jendle et al.
Journal of medical economics, 15 Suppl 2, 1-5 (2012-08-03)
The purpose of this study was to investigate the preferences of people with diabetes for liraglutide vs other glucose lowering drugs, based on outcomes of clinical trials. Willingness to pay (WTP) for diabetes drug treatment was assessed by combining results
Helena Atroch Machado et al.
Clinics (Sao Paulo, Brazil), 67(7), 711-717 (2012-08-16)
To compare the effects of glimepiride and metformin on vascular reactivity, hemostatic factors and glucose and lipid profiles in patients with type 2 diabetes. A prospective study was performed in 16 uncontrolled patients with diabetes previously treated with dietary intervention.
Lan Gao et al.
International journal of technology assessment in health care, 28(4), 436-444 (2012-09-26)
The aim of this study was to evaluate the long-term cost-utility of liraglutide versus glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM), based on the results of clinical trial conducted in Asian population. The
Subbiah Sridhar et al.
Clinical endocrinology, 78(3), 454-459 (2012-07-24)
Pioglitazone is an insulin sensitizer used for the management of type 2 diabetes mellitus (T2DM). It has been shown to reduce testosterone level in patients with polycystic ovarian syndrome. However, its effect on testosterone in men has not been studied.
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico